Розробки для медицини - ІМВ НАН України 🇺🇦


A highly effective drug for the prevention and treatment of dysbacteriosis and acute diseases of the human gastrointestinal tract.

The drug BIOSPORYN is an association of cultures of microorganisms that have high antagonistic activity against pathogenic and opportunistic microorganisms that cause dysbacteriosis of various etiologies. The first domestic probiotic for human treatment. Substitute of antibiotics.

Available documentation: Патент України. Нормативно-технічна документація: Регламент на виробництво готової лікарської форми, Фармакопейна стаття на готову лікарську форму.


Highly effective biological preparation created on the basis of aerobic spore-forming bacteria, which have high antiviral and antibacterial activity. The drug is effective against the causative agents of viral infections, such as influenza, herpes, Venezuelan encephalomyelitis, and also has high antagonistic activity against a wide range of pathogenic and opportunistic microorganisms. The combination of antibacterial and antiviral properties in an aqueous preparation is a fundamentally new approach to the treatment of many diseases of mixed etiology.

Available documentation: Патент України. Нормативно-технічна документація: Технічні умови на готову лікарську форму.


A new antibiotic batumin, highly active against staphylococci, was isolated from the new species "Pseudomonas batumici" at the Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine. The chemical structure of the antibiotic has been discovered. According to its chemical structure, it has no analogues among antibiotics used in practical medicine. Batumin has a unique selective activity against all studied species of staphylococci and shows moderate activity against representatives of other taxonomic groups. The selectivity of batumin against staphylococci is its fundamental difference from antibiotics that act only on gram-positive bacteria and from broad-spectrum antibiotics. When using batumin, the risk of developing resistance to it in microorganisms - representatives of the commensal microflora is minimized. Batumin also reduces biofilm formation in staphylococci and microorganisms of other taxonomic groups, which allows it to be considered not only as an antimicrobial drug, but also as an antibiotic that has an anti-persistence effect on pathogens.

The medicinal form of the antibiotic, an ointment containing 0.1% sodium salt of batumin, has shown high efficiency in the treatment of nasal carriage of S. aureus in medical personnel and patients, and is also an effective remedy for the treatment of purulent-inflammatory skin infections of staphylococcal etiology. Batumin plays an important role in the elimination of methicillin-resistant staphylococci during outbreaks of hospital infection - one of the acute and still unsolved problems of modern medicine.

Available documentation: Patent in Ukraine, Pharmacopoeia article.


Highly effective natural antioxidant, biostimulant and provitamin A. It is used to reduce damage caused by reactive oxygen, phototoxic molecules and chemical radicals during radioactive exposure of the body, as well as for the prevention and treatment of cancer and cardiovascular diseases. The drug protects membranes and stimulates the regeneration of cells, especially the liver, reduces inflammatory processes of the skin and mucous membranes, increases the body's resistance to infectious diseases, completely replaces vitamin A and improves visual acuity.

Available documentation: Patent in Ukraine. Regulatory and technical documentation: Technical conditions, Laboratory regulations, Toxic and hygienic passport.


Analytical enzyme used to determine galactose and its derivatives in various biological materials. In the institute, the producer of GALACTOSE OXIDASE was selected and the technology for obtaining the enzyme was developed.

The main advantages of the drug in comparison with analogues are high specificity and the absence of impurities of other enzymatic activities. It is used in medical practice to diagnose the hereditary disease of children with galactosemia, as well as in research work.

Available documentation: Regulatory and technical documentation: Technical conditions, Instructions for use of the drug.


Enzyme of fungal origin. Its producer is the fungus Penicillium vitale Pidopl. et Bilai. The drug is characterized by high antimicrobial activity, delays the growth of staphylococci and a number of pathogenic dermatophytes.

GLUCOSE OXIDASE is used in medicine as an antimicrobial drug with a wide spectrum of action for the treatment of purulent-surgical diseases; in the food industry, as well as as a reagent for evaluation of glucose in biological fluids.


The high selectivity of batumin against specie of the genus Staphylococcus was used to create a new diagnostic drug "Diastaf" (paper discs with 5 μg of batumin). The results of clinical trials of the drug "Diastaf" proved high specificity of this method of identification of staphylococci of various species in mono- and mixed cultures and the feasibility of using discs with batumin for preliminary urgent indication of staphylococci. The drug "Diastaf" proved to be highly effective in identifying atypical forms of staphylococci, the diagnosis of which is complicated even by molecular genetic methods. As a result of successful tests of the drug "Diastaf", the permission of the State Scientific and Expert Center for Medicines of the Ministry of Health of Ukraine was obtained for the release of a new diagnostic drug and its use in clinical institutions of Ukraine. It is characterized by a unique selectivity of action against staphylococci. The use of discs with an antibiotic allows you to reliably and quickly (within 18 hours) differentiate staphylococci by the inhibition zone of growth around the disc from other gram-positive cocci that are insensitive to the drug. DIASTAF does not affect the development of microorganisms of other taxa and provides rapid diagnosis of staphylococci in mixed cultures. The drug is intended for the detection of staphylococci in clinical, veterinary and research institutions.


A new highly effective drug obtained from the biomass of melanin-containing mushrooms. The drug has radioprotective, antioxidant, detoxifying and antitumor properties. It can be used in medicine and the food industry, as well as in the production of highly purified substances.

Available documentation: Patent of Ukraine. Regulatory and technical documentation: Regulations for the experimental batch.


The active substance of the drugs are immunoglobulins, which contain an increased amount of specific IgG. Their specific activity is due to the neutralizing effect of antibodies, as well as the immunomodulating effect that acts on various links of the human immune system and increases the non-specific resistance of the human body.

Available documentation: Package of Analytical regulatory documentation for specific human immunoglobulins. State registration of drugs.


The drug is used as an etiotropic and immunostimulating agent for the prevention of hepatitis A, measles, influenza, whooping cough, poliomyelitis and meningococcal infection, as well as for the treatment of hypo- and agammaglobulinemia, to increase the body's resistance during the period of convalescence after acute infections with a prolonged course.


A drug for the treatment of diseases caused by the common herpes virus type 1, including: encephalitis, encephalomyelitis, meningoencephalitis, arachnoencephalitis, arachnoiditis, encephalopolyradiculitis.


A drug for the treatment of diseases caused by herpes simplex virus type 2 with different clinical manifestations, namely: primary and recurrent urogenital infection in men and women, genital herpes infection in pregnant women, as well as associated obstetric pathology.


A drug for the treatment of cytomegalovirus infection with different clinical manifestations in adults and children, in particular, cytomegalovirus infection in pregnant women with a complicated obstetric history for the prevention of pregnancy disorders (prevention of the threat of miscarriage, the development of fetoplacental insufficiency, intrauterine fetal death); CMV infection in non-pregnant women with a complicated obstetric history to prevent disorders of the planned pregnancy; primary CMV infection in pregnant women with an unencumbered medical history to prevent obstetric complications; CMV infections in newborns and young children born to infected mothers and having clinical manifestations of the disease; CMV infections in adults with lesions of the central nervous system. 


A drug for the treatment of cytomegalovirus infection in patients with immunosuppression, including after transplantation, for the treatment of acute cytomegalovirus infection in patients with immunodeficiency, for example, in newborns, as well as in patients with drug immunosuppression or immunodeficiency caused by other causes, including AIDS.


A drug for the treatment of patients with herpes infection with damage to the nervous system caused by the Varicella Zoster virus (in particular, chicken pox, desiccated chicken pox, shingles).


A drug for the treatment of patients with herpes infection with damage to the nervous system caused by the herpes virus type 6 (sudden exanthema of newborns, acute febrile illness, non-febrile convulsions, chronic fatigue syndrome).


A drug for the treatment of infectious mononucleosis and diseases of the central and peripheral nervous system caused by the Epstein-Barr virus, including encephalitis, encephalomyelitis, meningoencephalitis, arachnoencephalitis, arachnoiditis, encephalopolyradiculitis.


A drug for the treatment of chlamydial infection, in particular with lesions of the urogenital tract, including salpingitis, salpingo-oophoritis, colpitis, urethritis, prostatitis, cystitis, urethroprostatitis, miscarriage, infertility.


A drug for the treatment of pregnant women with toxoplasmosis and associated obstetric pathology, as well as patients with lesions of the urogenital tract with toxoplasmosis.


A drug based on bacterial lectins for the prevention and treatment of influenza, herpes, hepatitis C and immunodeficiencies of various etiologies. Lectins have specificity for different types of sialic acid natural sialoconjugates, can be used also as analytical reagents for the study and purification of glycoproteins, as molecular probes for studying the structure of the cell surface.

 Available documentation: Patent of Ukraine. Regulatory and technical documentation: Technical conditions, Instructions for medical use, State registration of the drug.


Cyclopeptide antibiotic for the treatment of infections caused by pathogenic gram-negative microorganisms Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella and other bacteria resistant to known antibiotics. Polymyxin B is also used for the treatment of patients in a state of toxic shock caused by the bacteria listed above, and for the preparative release of toxins with which it forms complexes. Polymyxin B is less toxic than other polymyxins and can therefore be administered intramuscularly. With the help of genetic selection, highly active, non-mucous and phage-resistant strains of Bacillus polymyxa were obtained, which can be used in the industrial production of polymyxin B. A fermentation medium was proposed for the maximum production of the antibiotic during 72 hours of cultivation in an industrial fermenter. The ratio of B1, B2 and B3 components in the purified preparation of polymyxin B and its activity correspond to standard norms.


A new antitumor polyketide antibiotic from the angucycline family, which is synthesized by streptomycetes. The antitumor effect of landomycin E has been shown on 60 lines of wedge cancer at the US National Cancer Institute (Bethesda). Leukemia cells show the greatest sensitivity to the antibiotic. Landomycin E causes a typical process of programmed death (apoptosis) in cancer cells at a dose of 1-7 μg/ml. The antibiotic also shows its activity against cancer cells with multiple drug resistance, including those resistant to doxorubicin. Landomycin E has a weak mutagenic and moderate cytotoxic effect. The biotechnology of obtaining Landomycin E by fermentation of the highly active strain of streptomycete Streptomyces globisporus 1912-3 in an optimal medium was developed.